Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Array BioPharma"
Count: 54
Selected: 0
NCT IDTitle
NCT02278133Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
NCT01449058A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
NCT01820364LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
NCT01777776Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
NCT01561690A Study of ARRY-502 in Patients With Persistent Asthma
NCT00862524A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
NCT00859755A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
NCT00650767A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
NCT02109653Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
NCT00278902A Study of ARRY-334543 in Patients With Advanced Cancer
NCT00085787A Study of ARRY-142886 in Patients With Advanced Cancer
NCT00637702A Study of ARRY-334543 in Patients With Advanced Cancer
NCT01556568Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
NCT00952198A Safety Study of ARRY-403 in Patients With Type 2 Diabetes
NCT00833326A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
NCT00828165A Safety Study of ARRY-300 in Healthy Subjects
NCT00710736A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
NCT01469130A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
NCT01363232Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
NCT01349725A Safety Study of ARRY-502 in Healthy Subjects
NCT01352273MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
NCT01248923A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
NCT00462358A Study of ARRY-520 in Patients With Advanced Cancer
NCT01316822A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
NCT00790049A Safety Study of ARRY-371797 in Healthy Subjects
NCT00729209A Study of ARRY-371797 in Patients With Rheumatoid Arthritis
NCT02050815MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
NCT01801358A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
NCT00959127A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer
NCT01649336A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
NCT01496495A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
NCT00916227A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
NCT01859026A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
NCT04074967Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
NCT03374254Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
NCT01894672BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
NCT03843775A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
NCT02089230MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
NCT04598009Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
NCT01828034First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
NCT00650572A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
NCT02225574An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)
NCT02384083Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients
NCT04375527Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
NCT03158103A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT04292119Lorlatinib Combinations in Lung Cancer
NCT03231306Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
NCT01921335ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
NCT03170206Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
NCT04005144Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer